Pregnancy in Parkinson's disease: a review of the literature and a case report.
Identifieur interne : 004E65 ( Ncbi/Merge ); précédent : 004E64; suivant : 004E66Pregnancy in Parkinson's disease: a review of the literature and a case report.
Auteurs : P. Hagell [Suède] ; P. Odin ; E. VingeSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 1998.
English descriptors
- KwdEn :
- Abnormalities, Drug-Induced, Adjuvants, Pharmaceutic (therapeutic use), Adult, Amantadine (adverse effects), Animals, Antiparkinson Agents (therapeutic use), Aromatic Amino Acid Decarboxylase Inhibitors, Benserazide (therapeutic use), Dopamine Agents (therapeutic use), Enzyme Inhibitors (therapeutic use), Female, Humans, Levodopa (adverse effects), Mice, Parkinson Disease (drug therapy), Pregnancy, Pregnancy Complications (drug therapy), Pregnancy Outcome, Rabbits, Rats, Selegiline (adverse effects).
- MESH :
- chemical , adverse effects : Amantadine, Levodopa, Selegiline.
- chemical , therapeutic use : Adjuvants, Pharmaceutic, Antiparkinson Agents, Benserazide, Dopamine Agents, Enzyme Inhibitors.
- drug therapy : Parkinson Disease, Pregnancy Complications.
- Abnormalities, Drug-Induced, Adult, Animals, Aromatic Amino Acid Decarboxylase Inhibitors, Female, Humans, Mice, Pregnancy, Pregnancy Outcome, Rabbits, Rats.
Abstract
Pregnancy is rare in Parkinson's disease (PD). In the literature on studies of antiparkinsonian drugs in animals during pregnancy, there are reports on malformations of the skeletal and circulatory system. However, the majority of studies in animals have not shown any teratogenicity. Amantadine has been teratogenic in rats and selegiline has caused neurochemical and behavioral alterations in rats when coadministered with clorgyline. The published experience with humans consists of 35 pregnancies among 26 women suffering from PD, including this report, and a number of cases treated with antiparkinsonian agents for other reasons. With the exception of the majority of the cases where amantadine was used, complications have been rare. However, there are indications that suggest a possible risk of a woman's parkinsonism worsening in connection with pregnancy. We also report the case of a woman with PD who was treated with L-dopa-benserazide during an uncomplicated pregnancy and gave birth to a healthy boy without experiencing any worsening of her PD.
DOI: 10.1002/mds.870130110
PubMed: 9452323
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 004520
- to stream PubMed, to step Curation: 004520
- to stream PubMed, to step Checkpoint: 004354
Links to Exploration step
pubmed:9452323Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pregnancy in Parkinson's disease: a review of the literature and a case report.</title><author><name sortKey="Hagell, P" sort="Hagell, P" uniqKey="Hagell P" first="P" last="Hagell">P. Hagell</name><affiliation wicri:level="1"><nlm:affiliation>Section of Restorative Neurology, Wallenberg Neuroscience Center, University Hospital, Lund, Sweden.</nlm:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Section of Restorative Neurology, Wallenberg Neuroscience Center, University Hospital, Lund</wicri:regionArea><wicri:noRegion>Lund</wicri:noRegion></affiliation></author><author><name sortKey="Odin, P" sort="Odin, P" uniqKey="Odin P" first="P" last="Odin">P. Odin</name></author><author><name sortKey="Vinge, E" sort="Vinge, E" uniqKey="Vinge E" first="E" last="Vinge">E. Vinge</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1998">1998</date><idno type="RBID">pubmed:9452323</idno><idno type="pmid">9452323</idno><idno type="doi">10.1002/mds.870130110</idno><idno type="wicri:Area/PubMed/Corpus">004520</idno><idno type="wicri:Area/PubMed/Curation">004520</idno><idno type="wicri:Area/PubMed/Checkpoint">004354</idno><idno type="wicri:Area/Ncbi/Merge">004E65</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Pregnancy in Parkinson's disease: a review of the literature and a case report.</title><author><name sortKey="Hagell, P" sort="Hagell, P" uniqKey="Hagell P" first="P" last="Hagell">P. Hagell</name><affiliation wicri:level="1"><nlm:affiliation>Section of Restorative Neurology, Wallenberg Neuroscience Center, University Hospital, Lund, Sweden.</nlm:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Section of Restorative Neurology, Wallenberg Neuroscience Center, University Hospital, Lund</wicri:regionArea><wicri:noRegion>Lund</wicri:noRegion></affiliation></author><author><name sortKey="Odin, P" sort="Odin, P" uniqKey="Odin P" first="P" last="Odin">P. Odin</name></author><author><name sortKey="Vinge, E" sort="Vinge, E" uniqKey="Vinge E" first="E" last="Vinge">E. Vinge</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="1998" type="published">1998</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Abnormalities, Drug-Induced</term><term>Adjuvants, Pharmaceutic (therapeutic use)</term><term>Adult</term><term>Amantadine (adverse effects)</term><term>Animals</term><term>Antiparkinson Agents (therapeutic use)</term><term>Aromatic Amino Acid Decarboxylase Inhibitors</term><term>Benserazide (therapeutic use)</term><term>Dopamine Agents (therapeutic use)</term><term>Enzyme Inhibitors (therapeutic use)</term><term>Female</term><term>Humans</term><term>Levodopa (adverse effects)</term><term>Mice</term><term>Parkinson Disease (drug therapy)</term><term>Pregnancy</term><term>Pregnancy Complications (drug therapy)</term><term>Pregnancy Outcome</term><term>Rabbits</term><term>Rats</term><term>Selegiline (adverse effects)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Amantadine</term><term>Levodopa</term><term>Selegiline</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Adjuvants, Pharmaceutic</term><term>Antiparkinson Agents</term><term>Benserazide</term><term>Dopamine Agents</term><term>Enzyme Inhibitors</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term><term>Pregnancy Complications</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Abnormalities, Drug-Induced</term><term>Adult</term><term>Animals</term><term>Aromatic Amino Acid Decarboxylase Inhibitors</term><term>Female</term><term>Humans</term><term>Mice</term><term>Pregnancy</term><term>Pregnancy Outcome</term><term>Rabbits</term><term>Rats</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Pregnancy is rare in Parkinson's disease (PD). In the literature on studies of antiparkinsonian drugs in animals during pregnancy, there are reports on malformations of the skeletal and circulatory system. However, the majority of studies in animals have not shown any teratogenicity. Amantadine has been teratogenic in rats and selegiline has caused neurochemical and behavioral alterations in rats when coadministered with clorgyline. The published experience with humans consists of 35 pregnancies among 26 women suffering from PD, including this report, and a number of cases treated with antiparkinsonian agents for other reasons. With the exception of the majority of the cases where amantadine was used, complications have been rare. However, there are indications that suggest a possible risk of a woman's parkinsonism worsening in connection with pregnancy. We also report the case of a woman with PD who was treated with L-dopa-benserazide during an uncomplicated pregnancy and gave birth to a healthy boy without experiencing any worsening of her PD.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">9452323</PMID><DateCreated><Year>1998</Year><Month>03</Month><Day>26</Day></DateCreated><DateCompleted><Year>1998</Year><Month>03</Month><Day>26</Day></DateCompleted><DateRevised><Year>2014</Year><Month>11</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>1</Issue><PubDate><Year>1998</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Pregnancy in Parkinson's disease: a review of the literature and a case report.</ArticleTitle><Pagination><MedlinePgn>34-8</MedlinePgn></Pagination><Abstract><AbstractText>Pregnancy is rare in Parkinson's disease (PD). In the literature on studies of antiparkinsonian drugs in animals during pregnancy, there are reports on malformations of the skeletal and circulatory system. However, the majority of studies in animals have not shown any teratogenicity. Amantadine has been teratogenic in rats and selegiline has caused neurochemical and behavioral alterations in rats when coadministered with clorgyline. The published experience with humans consists of 35 pregnancies among 26 women suffering from PD, including this report, and a number of cases treated with antiparkinsonian agents for other reasons. With the exception of the majority of the cases where amantadine was used, complications have been rare. However, there are indications that suggest a possible risk of a woman's parkinsonism worsening in connection with pregnancy. We also report the case of a woman with PD who was treated with L-dopa-benserazide during an uncomplicated pregnancy and gave birth to a healthy boy without experiencing any worsening of her PD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hagell</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Section of Restorative Neurology, Wallenberg Neuroscience Center, University Hospital, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Odin</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Vinge</LastName><ForeName>E</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>UNITED STATES</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000277">Adjuvants, Pharmaceutic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D065105">Aromatic Amino Acid Decarboxylase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015259">Dopamine Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>14611-51-9</RegistryNumber><NameOfSubstance UI="D012642">Selegiline</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical><Chemical><RegistryNumber>762OS3ZEJU</RegistryNumber><NameOfSubstance UI="D001545">Benserazide</NameOfSubstance></Chemical><Chemical><RegistryNumber>BF4C9Z1J53</RegistryNumber><NameOfSubstance UI="D000547">Amantadine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Mov Disord. 1999 Jan;14(1):194</RefSource><PMID Version="1">9918378</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000014">Abnormalities, Drug-Induced</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000277">Adjuvants, Pharmaceutic</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000547">Amantadine</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000978">Antiparkinson Agents</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D065105">Aromatic Amino Acid Decarboxylase Inhibitors</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001545">Benserazide</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015259">Dopamine Agents</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004791">Enzyme Inhibitors</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007980">Levodopa</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011247">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D011248">Pregnancy Complications</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011256">Pregnancy Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011817">Rabbits</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012642">Selegiline</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>40</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1998</Year><Month>2</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1998</Year><Month>2</Month><Day>6</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1998</Year><Month>2</Month><Day>6</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">9452323</ArticleId><ArticleId IdType="doi">10.1002/mds.870130110</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Suède</li></country></list><tree><noCountry><name sortKey="Odin, P" sort="Odin, P" uniqKey="Odin P" first="P" last="Odin">P. Odin</name><name sortKey="Vinge, E" sort="Vinge, E" uniqKey="Vinge E" first="E" last="Vinge">E. Vinge</name></noCountry><country name="Suède"><noRegion><name sortKey="Hagell, P" sort="Hagell, P" uniqKey="Hagell P" first="P" last="Hagell">P. Hagell</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004E65 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 004E65 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:9452323
|texte= Pregnancy in Parkinson's disease: a review of the literature and a case report.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:9452323" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |